Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that on Monday 8^th and Tuesday 9^th May 2017, Professor Chris Nutting, Non-Executive Director of the Company, purchased a total of 202,500 ordinary shares of 25 pence in the Company at an average price of 24.67 pence per Ordinary Share.

Following these transactions, Professor Nutting holds 217,316 Ordinary Shares, representing 0.29% of the Company’s share capital as enlarged by the issue of new Ordinary Shares notified on 8^th May 2017. 

Advanced Oncotherapy Plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: +44 20 3617 8728
Nicolas Serandour, CEO
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: +44 20 7601 6100
Stifel Nicolaus Europe (Joint Broker)
Jonathan Senior / Ben Maddison	Tel: +44 20 7710 7600
Walbrook PR (Financial PR & IR)	Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy	Mob: +44 7980 541 893 / Mob: +44 7876 741 001